Q-omics provides the consensus-scored MFSD2A profile across patient tissues and cancer cell-line models. MFSD2A expression is associated with patient survival in 24 of 34 cancer types, with the highest sampling consensus in BLCA. Among the 18 cancer types available for tumor–normal comparison, MFSD2A is differentially expressed in 12, with the highest sampling consensus in LUAD. Additionally, MFSD2A RNA expression shows 15,815 significant gene co-expression associations, with the highest sampling consensus in UVM. Together, these results highlight BLCA, LUAD, and UVM as cancer lineages where MFSD2A shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for MFSD2A — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes MFSD2A survival associations across molecular data types. MFSD2A RNA expression shows survival associations in the most cancer types (24), followed by mutation status (3). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible MFSD2A RNA expression–survival associations across cancer types. High MFSD2A expression shows unfavorable associations in UVM, KIRC and LAML, but favorable associations in BLCA, LIHC and LUAD. The BLCA Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p < 0.001). Together, the overview and detailed table identify BLCA as the clearest survival context for MFSD2A RNA expression.
This table summarizes MFSD2A tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 12, while mass-spec protein shows differences in 1. The strongest signals are observed in LUSC for RNA and LSCC for protein.
This table ranks reproducible tumor–normal expression differences for MFSD2A. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. MFSD2A shows lower tumor expression in LUAD, LUSC, LIHC and KICH and higher tumor expression in HNSC and UCEC. The LUAD box plot shows higher MFSD2A RNA expression in normal versus tumor tissue (log2 FC = −2.956, t-test p < 0.001).
This table shows molecular features associated with MFSD2A in patient tissues and cancer cell lines. In patient samples, MFSD2A shows the broadest associations at the RNA and protein expression levels, with UVM recurring as the lineage with the largest associated feature set. In cancer cell lines, MFSD2A RNA and mutation anchors are most strongly linked to RNA-expression features, especially in OVARY, while CRISPR and shRNA rows add functional-dependency signals in BLOOD_Lymphoma and LARGE_INTESTINE.
